Up to 85% of atypical Alzheimer's patients may be ineligible for anti-amyloid therapies

A new study reveals that most people with atypical Alzheimer's (non-memory first presentations) are excluded from anti-amyloid therapies due to cognitive test biases. This challenges the one-size-fits-all approach and underscores the need for more inclusive diagnostic criteria and trial enrollment. For caregivers and patients, this highlights an advocacy opportunity and the importance of recognizing diverse presentations.